

**IN THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-48 (canceled)

49. (previously presented) A composition comprising two appetite suppressants, wherein each appetite suppressant is selected from the group consisting of

- (1) a CB-1 antagonist/inverse agonist; and
- (2) phentermine;

and pharmaceutically acceptable salts and esters thereof;

provided that the appetite suppressants have different biological mechanisms of action.

50. (previously presented) The composition of Claim 49 further comprising a pharmaceutically acceptable carrier.

51. (previously presented) A method of treating a subject having a disorder associated with excessive food intake comprising administration of a therapeutically effective amount of two appetite suppressants selected from the group consisting of

- (1) a CB-1 antagonist/inverse agonist; and
- (2) phentermine;

and pharmaceutically acceptable salts and esters thereof;

provided that the appetite suppressants have different biological mechanisms of action.

52. (previously presented) The method according to Claim 51 wherein the disorder associated with excessive food intake is obesity.

53. (previously presented) The method according to Claim 51 wherein the disorder associated with excessive food intake is an obesity-related disorder.

Claims 54 - 66 (canceled)